COVID-19 testing portfolio

Quest Diagnostics®

Antibody (serology)

Test name	Test code
SARS-CoV-2 Antibody (IgG), Spike, Semi-Quantitative	34499
SARS-CoV-2 Total Antibody, Spike, Semi-Quantitative	39820
SARS-CoV-2 Antibody (IgG), Nucleocapsid, Qualitative	39749
SARS-CoV-2 Antibodies (IgG Nucleocapsid, IgM Spike), Qualitative	31672

Active infection (molecular)

Test name	Test code
SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	39448

Rapid antigen

Test name
COVID-19 At-Home Rapid Antigen Test (2-Pack), Teleproctored, available via QuestDirect for Consumers

A positive SARS-CoV-2 spike antibody result indicates an immune response to a recent/prior infection or vaccination.
A positive SARS-CoV-2 nucleocapsid antibody result indicates an immune response to a recent or prior infection.

Cotesting

Test name	Test code
SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT	31688
SARS-CoV-2 RNA (COVID-19) and Influenza A/B and RSV RNA, Qualitative NAAT	39816
Panel name: SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT	31686
Components available for individual order: SARS-CoV-2 RNA	39448
Components available for individual order: Adenovirus	16046
Components available for individual order: Rhinovirus	40035
Components available for individual order: Enterovirus	15082
Components available for individual order: HMPV	40034
Components available for individual order: Influenza A and B RNA	16086
Other panel components: Influenza A subtype H1 Influenza A subtype H3 HPIV 1 HPIV 2 HPIV 3 HRSV A HRSV B	

Test name	Test code
Panel name: SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT	31687
Components available for individual order: SARS-CoV-2 RNA	39448
Components available for individual order: HPIV 1 HPIV 2 HPIV 3 HPIV 4	91228
Components available for individual order: Rhinovirus	40035
Components available for individual order: Enterovirus	15082
Components available for individual order: HMPV	40034
Components available for individual order: Adenovirus	16046
Components available for individual order: *Chlamydophila pneumoniae*	16003
Components available for individual order: *Mycoplasma pneumonia*	15498
Components available for individual order: Influenza A and B RNA	16086
Other panel components: Bocavirus Coronavirus 229e Coronavirus OC43 Coronavirus NL63 Coronavirus HKU1 HRSV A HRSV B Influenza A subtype H1 Influenza A subtype H3	

Test codes may vary by location. Please contact your local laboratory for more information.

Panel components may be ordered separately.

Antibody tests are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG and IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The tests should not be used to diagnose acute SARS-CoV-2 infection. False-positive results for the test may occur due to cross-reactivity from pre-existing antibodies or other possible causes. The sensitivity of the IgM test early after infection is unknown. Due to the risk of false-positive results, confirmation of positive results should be considered using a second, different IgM assay or an IgG assay. Samples should only be tested for IgM from individuals with 15 days to 30 days post–symptom onset. SARS-CoV-2 antibody negative samples collected 15 days or more post–symptom onset should be reflexed to a test that detects and reports SARS-CoV-2 IgG.

- The antibody tests have not been FDA cleared or approved
- The antibody tests have been authorized by FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories
- The antibody tests have been authorized only for detecting antibodies against SARS-CoV-2, not for any other viruses or pathogens
- The SARS-CoV-2 Total Antibody, Spike, Semi-Quantitative test has been authorized by FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform high complexity tests
- The IgM serology test component has been authorized only for the detection of IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens
- These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics.
All third-party marks—® and ™—are the property of their respective owners. © 2022 Quest Diagnostics Incorporated. All rights reserved. SB11144 8/2022